Story
Alligator Bioscience Stock Plummets Over 73% After Halting Lead Cancer Drug Program

Shares in Alligator Bioscience plummeted on Thursday after the Swedish biotechnology company announced it would halt the independent development of its lead drug candidate, mitazalimab, and launch a rights issue to strengthen its financial position.
Strategic Shift and Financial Measures
Alligator Bioscience said the decision follows a reassessment of the pancreatic cancer market, where recent advances in targeted therapies are altering the competitive landscape. The company now intends to out-license or divest mitazalimab and will refocus its efforts on its HLX22 project.
To shore up its finances, Alligator announced a series of measures, including:
- A proposed SEK 125.6 million rights issue, subject to shareholder approval.
- Undertakings and guarantees covering SEK 58.8 million, or 47% of the rights issue.
- Bridge loan agreements totaling SEK 19 million to secure near-term liquidity.
The company also stated it plans to wind down other activities and reduce its organizational size to minimize operating costs.
AdMarket Reaction
The market's response was severe. Alligator Bioscience's stock crashed 73.6% to SEK 0.0513 by 07:56 GMT, according to Investing.com. The dramatic sell-off reduced the company's market capitalization to just SEK 32.5 million.
Company Rationale
CEO Soren Bregenholt called the move a "very difficult but necessary decision." He explained that while the company believes mitazalimab has potential, the rapidly changing treatment landscape has made in-house development no longer commercially viable.
"In addition, we need to recognize that the resources required to reposition the program are not available to Alligator Bioscience," Bregenholt said in a statement. This pivot signals a significant strategic retreat from what was previously the company's flagship program.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.